%0 Journal Article %T Effects of Myocardial Phosphodiesterase 5 Inhibitors on the Left Ventricular Function in Patients With Heart Failure: A Randomized Clinical Trial %J Iranian Heart Journal %I Iranian Heart Association %Z %A Garakyaraghi, Mohammad %A Samadi, Mohsen %A Sadeghi, Masoumeh %A Givi, Mahshid %D 2018 %\ 03/01/2018 %V 19 %N 1 %P 61-67 %! Effects of Myocardial Phosphodiesterase 5 Inhibitors on the Left Ventricular Function in Patients With Heart Failure: A Randomized Clinical Trial %K Heart failure %K Left ventricular ejection fraction %K PDE5I %R %X Backgrounds: Myocardial phosphodiesterase 5 (PDE5) inhibitors are documented for use in variousdisease states. The efficacy of PDE5 inhibitors is less determined in heart failure patientswithout pulmonary hypertension. The aim of the present study was to evaluate the efficacy ofPDE5 inhibitors in heart failure patients without pulmonary hypertension.Method: Seventy-six cases with heart failure were participated in this study. The selection criteria weresystolic heart failure according to the New York Heart Association (NYHA) functionalclassifications I and IV, echocardiographically determined left ventricular ejection fraction lessthan 50%, and stability for at least 3 months. The participants were randomly divided into caseand control groups. Both case and control groups received 50 mg of sildenafil and a placebo for3 months, respectively. Transthoracic echocardiography (TTE) was performed using theVingmed 800 CSF. All the ejection fraction measurements were done using the Simpsonmethod. Before the initiation of the trial and then 3 months afterward, TTE was obtained fromthe participants. Changes in the functional class and the left ventricular ejection fraction beforeand after the trial were assessed and the data were analyzed using SPSS, version 16.Results: In the case group, the ejection fraction after the trial with an average of 41.53 ± 7.53 wasconsiderably more significant than that before the trial with an average of 37.92 ± 6.92(P < 0.001). The findings also showed that sildenafil inhibited PDE5 and the development ofthe NYHA IV when given for 90 days. As a result, sildenafil significantly improved the leftventricular ejection fraction.Conclusions: PDE5 inhibitors are effective in the treatment of heart failure patients without pulmonaryhypertension. %U http://journal.iha.org.ir/article_82807_94daef9240988280c8a5d482ec3b50b8.pdf